STOCK TITAN
  1. Home
  2. Sec-filings
  3. KZIA
  4. [EFFECT] KAZIA THERAPEUTICS LTD SEC Filing

[EFFECT] KAZIA THERAPEUTICS LTD SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 27, 2026 4:30 P.M.
Form: F-3
CIK: 0001075880
Company Name: KAZIA THERAPEUTICS LTD
File Number: 333-294392

Source: View Original Filing on SEC EDGAR

Kazia Therapeuti

NASDAQ:KZIA

View KZIA Stock Overview →

KZIA Rankings

#5182 Ranked by Market Cap
N/A Ranked by Dividends

KZIA Latest News

Jan 30, 2026
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Jan 27, 2026
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Jan 8, 2026
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Dec 22, 2025
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Dec 10, 2025
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

KZIA Latest SEC Filings

Mar 31, 2026
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 31, 2026
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 31, 2026
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 31, 2026
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 31, 2026
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer)

KZIA Stock Data

83.53M
10.00M
Biotechnology
Pharmaceutical Preparations
Link
Australia
NEW SOUTH WALES 2113